NCT07039942 French Prospective Multicentric Study in Real World
| NCT ID | NCT07039942 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Insulet Corporation |
| Condition | Diabetes |
| Study Type | OBSERVATIONAL |
| Enrollment | 304 participants |
| Start Date | 2025-07-23 |
| Primary Completion | 2027-05 |
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
The purpose of this postmarket clinical investigation is to evaluate the levels of glycemic control, quality of life, and satisfaction, as well as the patient experience, and acute diabetes complication rates provided by the Omnipod 5 Automated Insulin Delivery System (referred to as the Omnipod 5 System) in a real-world setting.
Eligibility Criteria
Inclusion Criteria: * Patient with T1D aged ≥ 2 years. * Patient prescribed a commercially available configuration of the Omnipod 5 System using a Dexcom sensor (Dexcom G6 or Dexcom G7). * Patient has never used the Omnipod 5 System prior to inclusion. * Patient has not objected to the use of their personal data for this study. * Patient or legal guardian has an email address and mobile phone number. * Patient (and legal guardians if the patient is a minor) is able to understand study information and Non-Opposition form. * Patient (and legal guardians if the patient is a minor) is able to understand and complete questionnaires in French. * Patient is covered by the local social security system. Exclusion Criteria: * Patient is currently pregnant * Patient presents an allergy to the materials of the Omnipod 5 System (patch, cannula, CGM). * Patient is unable to be followed by the same investigation site for the duration of the study or is unwilling or unable to maintain contact with the
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.